Yahoo Web Search

Search results

1. avttx.comAshvattha Therapeutics – Developing a New Class of ...

   avttx.com

   • Cached

   May 23, 2024 · Ashvattha Therapeutics is a biopharmaceutical company developing precision nanomedicines for ophthalmology, neurology, and inflammatory diseases. The nanomedicines use hydroxyl dendrimer technology to target activated cells in regions of inflammation.

2. People also ask

   Who is Ashvattha Therapeutics?

   • Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel precision nanomedicines enabled by our hydroxyl dendrimer (HD) technology to treat unmet medical needs in ophthalmology, neurology, and inflammatory diseases.

   Ashvattha Therapeutics – Developing a New Class of Intracellular

   avttx.com/

   See all results for this question

   What programs does Ashvattha offer?

   • Ashvattha has initiated multiple programs with HDTs focused on neurology, ocular neovascular disease including neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), and hyperinflammation in diseases. For more information, visit: www.avttx.com.

   Ashvattha Therapeutics Announces First Patient Enrolled in - GlobeNew…

   www.globenewswire.com/news-release/2022/09/07/2511439/0/en/Ashvattha-Therapeutics-Announces-First-Patient-Enrolled-in-a-Phase-2-Study-of-D-4517-2-for-the-Treatment-of-Wet-AMD-and-DME.html

   See all results for this question

   Could Ashvattha's hydroxyl dendrimer solve VEGF toxicity problems?

   • Covalently linking an anti-angiogenic small molecule to Ashvattha’s hydroxyl dendrimer creates a new chemical entity that could potentially solve the toxicity issues while retaining potency. In-vitro studies in hRPE cells with D-4517.2 demonstrated restoration of VEGF mRNA to normal, healthy levels.

   Ashvattha Therapeutics Announces First Patient Enrolled in - GlobeNew…

   www.globenewswire.com/news-release/2022/09/07/2511439/0/en/Ashvattha-Therapeutics-Announces-First-Patient-Enrolled-in-a-Phase-2-Study-of-D-4517-2-for-the-Treatment-of-Wet-AMD-and-DME.html

   See all results for this question

3. avttx.com › pipelinePipeline – Ashvattha Therapeutics

   avttx.com › pipeline

   • Cached

   Ashvattha Therapeutics is a biotech company developing nanomedicines for inflammatory and neurodegenerative diseases. Learn about their pipeline products, including D-4517.2 for wet AMD and DME, OP-801 for ALS, and OP-101 for COVID-19.

4. avttx.com › about-usAbout Us – Ashvattha Therapeutics

   avttx.com › about-us

   • Cached

   Scientific Advisory Board. Kannan Rangaramanujam, Ph.D. Co-founder, Board Observer, Co-Director, Center for Nanomedicine, Professor of Ophthalmology at Johns Hopkins University. Nicholas A. Peppas, Sc.D. University of Texas at Austin.

   • 
   • 
   • 
   • 

5. www.globenewswire.com › news-release › 2024/02/22Ashvattha Therapeutics Announces First Patient Enrolled in

   www.globenewswire.com › news-release › 2024/02/22

   • Cached

   Feb 22, 2024 · Ashvattha Therapeutics is a clinical-stage company developing nanomedicine therapeutics that target activated cells in regions of inflammation. It has enrolled the first patient in a Phase 1/2 study of 18F-OP-801, a PET imaging agent that can detect neuroinflammation in ALS, AD, MS and PD.

6. www.globenewswire.com › news-release › 2022/09/07Ashvattha Therapeutics Announces First Patient Enrolled in

   www.globenewswire.com › news-release › 2022/09/07

   • Cached

   Sep 7, 2022 · Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology,...

7. www.globenewswire.com › news-release › 2022/08/01Ashvattha Therapeutics Announces Preclinical Data at the

   www.globenewswire.com › news-release › 2022/08/01

   • Cached

   Aug 1, 2022 · Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology,...

8. www.businesswire.com › news › homeAshvattha Therapeutics Announces Positive Interim Data from ...

   www.businesswire.com › news › home

   • Cached

   Jun 15, 2021 · OP-101 is a novel hydroxyl dendrimer therapeutic that targets hyperinflammation and neuronal injury in severe COVID-19 patients. Interim data show improved survival, reduced inflammation and NfL levels, and no adverse events with OP-101.